Cannabidiol (CBD) Infusion into Healthcare Products Industry Growing Faster Than Expected - Seite 2
The infusion of Cannabidiol better known as CBD, has been recognized as one of the many compounds specifically found in the Hemp and Cannabis plant to help fight inflammation and reduce sebum
production in the skin. It is believed that Hemp-derived CBD, unlike THC, does not give the user a "high" feeling but more provides therapeutic effects for psoriasis, atopic dermatitis and eczema.
According to recent estimates from the Grand View Research Group, the skincare market is projected to grow to a $177 billion market by 2024; while research firm
Brightfield Group projects the CBD market to hit $1 billion in the next three years. Read this and more news for Cannabis Strategic Ventures
at: http://www.marketnewsupdates.com/news/nugs.html
Other recent developments and major influences in the cannabis industry include:
Sugarmade, Inc. (OTCPK:SGMD), one of the largest publicly traded hydroponics supply companies, yesterday announced SeeThruEquity has initiated coverage on the Company with a price target of
$0.30, with the reporting adding, "Sugarmade appears well-positioned to target the large and growing opportunity to supply hydroponics equipment and supplies to the
legal cultivation market in the United States through its master marketing agreement with BizRight." Jimmy Chan, CEO of Sugarmade
commented, "Having Sugarmade highlighted by SeeThruEquity is important to this management team. Over the past two years, Sugarmade has almost completely restructured. We have entered one of the
fast growing sectors of the American economy, reduced debt levels, added a significant number of personnel, moved our headquarters, and most importantly, positioned our Company for substantial
growth. Based on our growth rates, we now believe our $30 million revenue guidance for next year is very conservative. We welcome SeeThruEquity's research coverage and
look forward to supplying its analyst a steady stream of news on high quality developments regarding our progress.
Lesen Sie auch
Pyramidion Technology Group, Inc. (OTCPK:PYTG) yesterday announced that Dr. David M. Feldbaum MD, Fellow, American College of Surgeons (FACS), has been appointed to the Board of Advisors for PYTG. David M. Feldbaum MD, FACS is certified in vascular surgery by the American Board of Surgery. Dr. Feldbaum completed a surgical residency at Montefiore Medical Center/Albert Einstein College of Medicine in New York City, and a vascular surgery fellowship at the Carolinas Heart Institute in North Carolina. He is affiliated with the Memorial Healthcare System, and Westside Regional Medical Center. He is also a member of the voluntary faculty clinical instructor of surgery at the University of Miami School of Medicine. Dr. Feldbaum's presence on the Board of Advisors seeks to bolster its already credential-filled advisory capacity by offering instrumental input on the implementation of whole-care wellness plans, and specific case-relevant treatment plans, related to his area of expertise. Dr. Feldbaum has a unique interest in Medical Cannabis affairs and is a strong advocate of the use of Cannabidiol (CBD) products as part of a health and wellness program for many patients.